Email Alert RSS
Volume 12 Issue 4
Jul.  2021
Turn off MathJax
Article Contents
Abstract
References
Related Articles
LIANG Xiaojie, WANG Liang. Current Status of the Diagnosis and Treatment of Primary Intraocular Lymphoma[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(4): 537-543. DOI: 10.12290/xhyxzz.20190100
Citation: LIANG Xiaojie, WANG Liang. Current Status of the Diagnosis and Treatment of Primary Intraocular Lymphoma[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(4): 537-543. DOI: 10.12290/xhyxzz.20190100
shu

Current Status of the Diagnosis and Treatment of Primary Intraocular Lymphoma

  • 1.

    First Clinical Medical College, Southern Medical University, Guangzhou 510515, China

  • 2.

    Department of Hematology, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China

Funds: 

National Natural Science Foundation of China 81873450

More Information
  • Corresponding author:

    WANG Liang  Tel：86-10-58268442，E-mail：wangliangtrhos@126.com

  • Received Date: June 03, 2019
  • Accepted Date: October 11, 2019
  • Available Online: October 11, 2019
  • Issue Publish Date: July 29, 2021
    Graphical Abstract
    • Abstract
  • Primary intraocular lymphoma (PIOL) is a rare non-Hodgkin lymphoma and classified as a special subtype of primary central nervous system lymphoma (PCNSL). At present, the diagnosis of PIOL still faces some challenges because it can masquerade as uveitis, behcet disease and so on. Its histopathologic biopsy remains the standard approach to diagnose PIOL. Gene detection, flow cytometry analysis, and determination of cytokine levels can increase the diagnostic accuracy of PIOL. Currently, there are no standard therapies for PIOL, although local radiotherapy, intravitreal chemotherapy and high-dose systemic chemotherapy are effective to control it. However, the prognosis of PIOL is poor because it is prone to local recurrence and developing into PCNSL.Therefore, early diagnosis and treatment are very important for the prognosis of PIOL.
    • FullText(HTML)
    • References (45)
  • [1]
    Tang LJ, Gu CL, Zhang P. Intraocular lymphoma[J]. Int J Ophthalmol, 2017, 10: 1301-1307.
    [2]
    Chaput F, Amer R, Baglivo E, et al. Intraocular T-cell Lymphoma: Clinical Presentation, Diagnosis, Treatment, and Outcome[J]. Ocul Immunol Inflamm, 2017, 25: 639-648. http://europepmc.org/abstract/MED/27002464
    [3]
    Bohn JP, Willenbacher W, Haas G, et al. Pomalidomide in primary intraocular lymphoma[J]. Leuk Lymphoma, 2019, 60: 1584-1586. DOI: 10.1080/10428194.2018.1538508
    [4]
    Cho BJ, Yu HG. Risk factors for intraocular involvement in patients with primary central nervous system lymphoma[J]. J Neurooncol, 2014, 120: 523-529. DOI: 10.1007/s11060-014-1581-4
    [5]
    Mochizuki M, Singh AD. Epidemiology and clinical features of intraocular lymphoma[J]. Ocul Immunol Inflamm, 2009, 17: 69-72. DOI: 10.1080/09273940902957305
    [6]
    Goto H, Mochizuki M, Yamaki K, et al. Epidemiological survey of intraocular inflammation in Japan[J]. Jpn J Ophthalmol, 2007, 51: 41-44. DOI: 10.1007/s10384-006-0383-4
    [7]
    Sagoo MS, Mehta H, Swampillai AJ, et al. Primary intraocular lymphoma[J]. Surv Ophthalmol, 2014, 59: 503-516. DOI: 10.1016/j.survophthal.2013.12.001
    [8]
    Chan CC, Rubenstein JL, Coupland SE, et al. Primary vitreoretinal lymphoma: a report from an International Primary Central Nervous System Lymphoma Collaborative Group symposium[J]. Oncologist, 2011, 16: 1589-1599. DOI: 10.1634/theoncologist.2011-0210
    [9]
    Chan CC. Primary intraocular lymphoma: clinical features, diagnosis, and treatment[J]. Clin Lymphoma, 2003, 4: 30-31. DOI: 10.1016/S1526-9655(11)70005-7
    [10]
    Kimura K, Usui Y, Goto H. Clinical features and diagno-stic significance of the intraocular fluid of 217 patients with intraocular lymphoma[J]. Jpn J Ophthalmol, 2012, 56: 383-389. DOI: 10.1007/s10384-012-0150-7
    [11]
    Mashayekhi A, Shukla SY, Shields JA, et al. Choroidal lymphoma: clinical features and association with systemic lymphoma[J]. Ophthalmology, 2014, 121: 342-351. DOI: 10.1016/j.ophtha.2013.06.046
    [12]
    Kiratli H, Ağin A, Büyükeren B, et al. Primary Diffuse Large B-Cell Lymphoma of the Ciliary Body[J]. Ocul Immunol Inflamm, 2019, 27: 407-409. DOI: 10.1080/09273948.2017.1415362
    [13]
    Chan CC, Sen HN. Current concepts in diagnosing and managing primary vitreoretinal (intraocular) lymphoma[J]. Discov Med, 2013, 15: 93-100.
    [14]
    Casady M, Faia L, Nazemzadeh M, et al. Fundus autofluorescence patterns in primary intraocular lymphoma[J]. Retina, 2014, 34: 366-372. DOI: 10.1097/IAE.0b013e31829977fa
    [15]
    Majumder PD, Raghothaman N, Kharel R, et al. Retinal necrosis as the initial presentation of primary intraocular lymphoma[J]. Nepal J Ophthalmol, 2017, 9: 83-86. DOI: 10.3126/nepjoph.v9i1.17541
    [16]
    Grimm SA, McCannel CA, Omuro AM, et al. Primary CNS lymphoma with intraocular involvement: International PCNSL Collaborative Group Report[J]. Neurology, 2008, 71: 1355-1360. DOI: 10.1212/01.wnl.0000327672.04729.8c
    [17]
    Hwang CS, Yeh S, Bergstrom CS. Diagnostic vitrectomy for primary intraocular lymphoma: when, why, how?[J]. Int Ophthalmol Clin, 2014, 54: 155-171. DOI: 10.1097/IIO.0000000000000022
    [18]
    Fend F, Ferreri AJ, Coupland SE. How we diagnose and treat vitreoretinal lymphoma[J]. Br J Haematol, 2016, 173: 680-692. DOI: 10.1111/bjh.14025
    [19]
    Konstantinidis L, Angi M, Coupland SE, et al. Primary B-cell lymphoma of the ciliary body with 360° ('ring'-like) growth pattern[J]. Eye (Lond), 2014, 28: 355-356. DOI: 10.1038/eye.2013.282
    [20]
    Hoang-Xuan K, Bessell E, Bromberg J, et al. Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology[J]. Lancet Oncol, 2015, 16: e322-e332. DOI: 10.1016/S1470-2045(15)00076-5
    [21]
    Keino H, Okada AA, Watanabe T, et al. Spectral-domain Optical Coherence Tomography Patterns in Intraocular Lymphoma[J]. Ocul Immunol Inflamm, 2016, 24: 268-273. http://europepmc.org/abstract/med/25760916
    [22]
    Fardeau C, Lee CP, Merle-Béral H, et al. Retinal fluorescein, indocyanine green angiography, and optic coher-ence tomography in non-Hodgkin primary intraocular lymphoma[J]. Am J Ophthalmol, 2009, 147: 886-894. DOI: 10.1016/j.ajo.2008.12.025
    [23]
    Davis JL, Viciana AL, Ruiz P. Diagnosis of intraocular lymphoma by flow cytometry[J]. Am J Ophthalmol, 1997, 124: 362-372. DOI: 10.1016/S0002-9394(14)70828-1
    [24]
    Missotten T, Tielemans D, Bromberg JE, et al. Multicolor flowcytometric immunophenotyping is a valuable tool for detection of intraocular lymphoma[J]. Ophthalmology, 2013, 120: 991-996. DOI: 10.1016/j.ophtha.2012.11.007
    [25]
    Hiemcke-Jiwa LS, Ten Dam-van Loon NH, Leguit RJ, et al. Potential Diagnosis of Vitreoretinal Lymphoma by Detection of MYD88 Mutation in Aqueous Humor With Ultrasensitive Droplet Digital Polymerase Chain Reaction[J]. JAMA Ophthalmol, 2018, 136: 1098-1104. DOI: 10.1001/jamaophthalmol.2018.2887
    [26]
    Tuo J, Shen D, Yang HH, et al. Distinct microRNA-155 expression in the vitreous of patients with primary vitreore-tinal lymphoma and uveitis[J]. Am J Ophthalmol, 2014, 157: 728-734. DOI: 10.1016/j.ajo.2013.12.014
    [27]
    Ohta K, Sano K, Imai H, et al. Cytokine and molecular analyses of intraocular lymphoma[J]. Ocul Immunol Inflamm, 2009, 17: 142-147. DOI: 10.1080/09273940802702553
    [28]
    Cassoux N, Giron A, Bodaghi B, et al. IL-10 measurement in aqueous humor for screening patients with suspicion of primary intraocular lymphoma[J]. Invest Ophthalmol Vis Sci, 2007, 48: 3253-3259. DOI: 10.1167/iovs.06-0031
    [29]
    Wolf LA, Reed GF, Buggage RR, et al. Vitreous cytokine levels[J]. Ophthalmology, 2003, 110: 1671-1672. DOI: 10.1016/S0161-6420(03)00811-X
    [30]
    Kim MM, Dabaja BS, Medeiros J, et al. Survival Outcomes of Primary Intraocular Lymphoma: A Single-institution Experience[J]. Am J Clin Oncol, 2016, 39: 109-113. DOI: 10.1097/COC.0000000000000028
    [31]
    Levasseur SD, Wittenberg LA, White VA. Vitreoretinal lymphoma: a 20-year review of incidence, clinical and cytologic features, treatment, and outcomes[J]. JAMA Ophthalmol, 2013, 131: 50-55. DOI: 10.1001/jamaophthalmol.2013.569
    [32]
    Milgrom SA, Cheah CY, Pinnix CC, et al. Acute and late toxicity of bilateral orbital irradiation in the management of primary intraocular lymphoma[J]. Leuk Lymphoma, 2016, 57: 2612-2618. DOI: 10.3109/10428194.2016.1166490
    [33]
    Teckie S, Yahalom J. Primary intraocular lymphoma: treatment outcomes with ocular radiation therapy alone[J]. Leuk Lymphoma, 2014, 55: 795-801. DOI: 10.3109/10428194.2013.819576
    [34]
    Ma WL, Hou HA, Hsu YJ, et al. Clinical outcomes of primary intraocular lymphoma patients treated with front-line systemic high-dose methotrexate and intravitreal methotrexate injection[J]. Ann Hematol, 2016, 95: 593-601. DOI: 10.1007/s00277-015-2582-x
    [35]
    Tempescul A, Pradier O, Marianowski-Cochard C, et al. Combined therapy associating systemic platinum-based chemotherapy and local radiotherapy into the treatment of primary intraocular lymphoma[J]. Ann Hematol, 2011, 90: 1117-1118. DOI: 10.1007/s00277-010-1139-2
    [36]
    Frenkel S, Hendler K, Siegal T, et al. Intravitreal methotrexate for treating vitreoretinal lymphoma: 10 years of experience[J]. Br J Ophthalmol, 2008, 92: 383-388. DOI: 10.1136/bjo.2007.127928
    [37]
    Kitzmann AS, Pulido JS, Mohney BG, et al. Intraocular use of rituximab[J]. Eye (Lond), 2007, 21: 1524-1527. DOI: 10.1038/sj.eye.6702804
    [38]
    Kim H, Csaky KG, Chan CC, et al. The pharmacok-inetics of rituximab following an intravitreal injection[J]. Exp Eye Res, 2006, 82: 760-766. DOI: 10.1016/j.exer.2005.09.018
    [39]
    Ghesquieres H, Chevrier M, Laadhari M, et al. Lenalido-mide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective'proof of concept'phase Ⅱ study of the French Oculo-Cerebral lymphoma (LOC) Network and the Lymphoma Study Association (LYSA)†[J]. Ann Oncol, 2019, 30: 621-628. DOI: 10.1093/annonc/mdz032
    [40]
    Lionakis MS, Dunleavy K, Roschewski M, et al. Inhibi-tion of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma[J]. Cancer Cell, 2017, 31: 833-843. DOI: 10.1016/j.ccell.2017.04.012
    [41]
    Wang L, Guan W, Peng X. Targeting Bruton Tyrosine Kinase With Zanubrutinib for Treatment of Vitreoretinal Lymphoma: Report of 3 Cases[J]. Front Oncol, 2021, 11: 676792. DOI: 10.3389/fonc.2021.676792
    [42]
    Goodman A, Patel SP, Kurzrock R. PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas[J]. Nat Rev Clin Oncol, 2017, 14: 203-220. DOI: 10.1038/nrclinonc.2016.168
    [43]
    Nayak L, Iwamoto FM, LaCasce A, et al. PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma[J]. Blood, 2017, 129: 3071-3073. DOI: 10.1182/blood-2017-01-764209
    [44]
    Schorb E, Finke J, Ihorst G, et al. Age-adjusted high-dose chemotherapy and autologous stem cell transplant in elderly and fit primary CNS lymphoma patients[J]. BMC Cancer, 2019, 19: 287. DOI: 10.1186/s12885-019-5473-z
    [45]
    Ferreri AJ, Blay JY, Reni M, et al. Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience[J]. J Clin Oncol, 2003, 21: 266-272. DOI: 10.1200/JCO.2003.09.139
    • Related Articles

  • Related Articles

    [1]CUI Hanshu, LIU Bin. Controversy About Management of Osteoarthritis with Disease-modifying Anti-rheumatic Drugs[J]. Medical Journal of Peking Union Medical College Hospital, 2025, 16(1): 13-18. DOI: 10.12290/xhyxzz.2024-0802
    [2]ZHAO Yafang, ZHANG Chunyan, CUI Shuang. Characteristics and Associated Factors of Autoimmune Diseases-related Skin Ulcer: A Multi Center Study[J]. Medical Journal of Peking Union Medical College Hospital. DOI: 10.12290/xhyxzz.2024-0622
    [3]LIU Huan, HUANG Xiaoling, DAI Mengying, GUO Jiejie, GAO feng. Clinical Characteristics and Inflammatory Markers of Omicron BA.5.2 Variant Infection in Hospitalized Patients and Their Predictive Role in Disease Prognosis[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(5): 1038-1045. DOI: 10.12290/xhyxzz.2023-0055
    [4]WU Ziyan, FENG Futai, LI Haolong, XU Honglin, ZHANG Shulan, LI Yongzhe. Quantitative Analysis of Mitochondrial Damage in T Lymphocytes from Patients with Autoimmune Diseases and Evaluation of Its Clinical Value[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(5): 991-998. DOI: 10.12290/xhyxzz.2023-0256
    [5]ZHANG Lu, LI Jian. Castleman Disease in China: State-of-the-art Technology Before the Era of IL-6 Targeted Therapy[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(5): 911-914. DOI: 10.12290/xhyxzz.2023-0227
    [6]MA Mingsheng, SONG Hongmei. Acceleration of Precision Medicine in Pediatric Rheumatic and Immunologic Diseases[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(2): 229-233. DOI: 10.12290/xhyxzz.2023-0080
    [7]JIANG Xu, YANG Huaxia, ZHANG Fengchun. The Role of the Gut Microbial Metabolites in Autoimmune Diseases[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(5): 747-752. DOI: 10.12290/xhyxzz.2022-0246
    [8]ZHAO Lidan, MENG Xia, XU Haojie, ZHANG Fengchun. Prospect of Gut Microbiota-based Intervention in Autoimmune Disease Control[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(5): 740-746. DOI: 10.12290/xhyxzz.2022-0245
    [9]XIE Jing, WU Dong, ZHANG Shu-yang. Public Health Ethics and Clinical Practice in the Context of Response to the Outbreak of an Infectious Disease[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(1): 141-145. DOI: 10.12290/xhyxzz.20200249
    [10]Feng-chun ZHANG. What do We Need to Know about Rheumatology[J]. Medical Journal of Peking Union Medical College Hospital, 2017, 8(4-5): 204-206. DOI: 10.3969/j.issn.1674-9081.2017.05.002

Catalog

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (1148) PDF downloads (245) Cited by()
    Related
    Links: National Health Commission of the People's Republic of China Chinese Academy of Medical Sciences(CAMS) AMLC Check CNKI Database CNKI Term Online Chinese General Practice
    Address：Room 302,Third Floor,Building 7, No. 1 Shuaifuyuan, Wangfujing, Dongcheng District, Beijing 100730, China
    Tel：010-69154261/4262
    E - mail：medj@pumch.cn mjpumch@126.com
    Copyright of website：Editorial Office of Medical Journal of Peking Union Medical College Hospital

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return
    x Close Forever Close